215 related articles for article (PubMed ID: 11522186)
21. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.
Cihlar T; Birkus G; Greenwalt DE; Hitchcock MJ
Antiviral Res; 2002 Apr; 54(1):37-45. PubMed ID: 11888656
[TBL] [Abstract][Full Text] [Related]
23. In vitro selection and characterization of human immunodeficiency virus type 1 resistant to Zidovudine and tenofovir.
Park SS; Hong SK; Lee SG; Yoon JS; Yoo WC; Paik SY
Nucleosides Nucleotides Nucleic Acids; 2007; 26(5):453-7. PubMed ID: 17578743
[TBL] [Abstract][Full Text] [Related]
24. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
[TBL] [Abstract][Full Text] [Related]
25. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
Miller MD; Anton KE; Mulato AS; Lamy PD; Cherrington JM
J Infect Dis; 1999 Jan; 179(1):92-100. PubMed ID: 9841827
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
27. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
28. International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.
Grant PM; Taylor J; Nevins AB; Calvez V; Marcelin AG; Wirden M; Zolopa AR
Antimicrob Agents Chemother; 2010 Apr; 54(4):1520-5. PubMed ID: 20124005
[TBL] [Abstract][Full Text] [Related]
29. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Wainberg MA; Miller MD; Quan Y; Salomon H; Mulato AS; Lamy PD; Margot NA; Anton KE; Cherrington JM
Antivir Ther; 1999; 4(2):87-94. PubMed ID: 10682153
[TBL] [Abstract][Full Text] [Related]
30. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.
Margot NA; Miller MD
Antivir Ther; 2005; 10(2):343-8. PubMed ID: 15865229
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
Kearney BP; Flaherty JF; Shah J
Clin Pharmacokinet; 2004; 43(9):595-612. PubMed ID: 15217303
[TBL] [Abstract][Full Text] [Related]
32. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?
Naeger LK; Miller MD
Curr Opin Investig Drugs; 2001 Mar; 2(3):335-9. PubMed ID: 11575701
[TBL] [Abstract][Full Text] [Related]
34. Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
Marchand B; White KL; Ly JK; Margot NA; Wang R; McDermott M; Miller MD; Götte M
Antimicrob Agents Chemother; 2007 Aug; 51(8):2911-9. PubMed ID: 17517852
[TBL] [Abstract][Full Text] [Related]
35. Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Maeda K; Desai DV; Aoki M; Nakata H; Kodama EN; Mitsuya H
Antivir Ther; 2014; 19(2):179-89. PubMed ID: 24162098
[TBL] [Abstract][Full Text] [Related]
36. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
Mastroianni CM; d'Ettorre G; Vullo V
Expert Opin Pharmacother; 2006 Nov; 7(16):2233-41. PubMed ID: 17059380
[TBL] [Abstract][Full Text] [Related]
37. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Lambert-Niclot S; Charpentier C; Storto A; Fofana D; Soulie C; Fourati S; Wirden M; Morand-Joubert L; Masquelier B; Flandre P; Calvez V; Descamps D; Marcelin AG
J Antimicrob Chemother; 2014 Apr; 69(4):1086-9. PubMed ID: 24302653
[TBL] [Abstract][Full Text] [Related]
38. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
39. Tenofovir disoproxil fumarate.
Grim SA; Romanelli F
Ann Pharmacother; 2003 Jun; 37(6):849-59. PubMed ID: 12773076
[TBL] [Abstract][Full Text] [Related]
40. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Parkin N; Chappey C; Maroldo L; Bates M; Hellmann NS; Petropoulos CJ
J Acquir Immune Defic Syndr; 2002 Oct; 31(2):128-36. PubMed ID: 12394790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
